SpringWorks Therapeutics has filed to raise $115 million in an IPO. The money will take SpringWorks through to regulatory filings for two former Pfizer drugs against rare tumors.
Pfizer licensed the drugs, gamma secretase inhibitor nirogacestat and MEK inhibitor mirdametinib, to SpringWorks in 2017. more